Literature DB >> 26779453

Cognitive/Clinical Endpoints for Pre-Dementia AD Trials.

P S Aisen1.   

Abstract

Entities:  

Year:  2015        PMID： 26779453      PMCID： PMC4713036          DOI： 10.14283/jpad.2015.62

Source DB:  PubMed          Journal:  J Prev Alzheimers Dis        ISSN： 2274-5807


× No keyword cloud information.
  22 in total

1.  Estimating long-term multivariate progression from short-term data.

Authors:  Michael C Donohue; Hélène Jacqmin-Gadda; Mélanie Le Goff; Ronald G Thomas; Rema Raman; Anthony C Gamst; Laurel A Beckett; Clifford R Jack; Michael W Weiner; Jean-François Dartigues; Paul S Aisen
Journal:  Alzheimers Dement       Date:  2014-03-20       Impact factor: 21.566

2.  Cognitive and functional decline and their relationship in patients with mild Alzheimer's dementia.

Authors:  Hong Liu-Seifert; Eric Siemers; Karen Sundell; Karen Price; Baoguang Han; Katherine Selzler; Paul Aisen; Jeffrey Cummings; Joel Raskin; Richard Mohs
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

3.  The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy.

Authors:  R C Mohs; W G Rosen; K L Davis
Journal:  Psychopharmacol Bull       Date:  1983

4.  The relative efficiency of time-to-threshold and rate of change in longitudinal data.

Authors:  M C Donohue; A C Gamst; R G Thomas; R Xu; L Beckett; R C Petersen; M W Weiner; P Aisen
Journal:  Contemp Clin Trials       Date:  2011-04-30       Impact factor: 2.226

Review 5.  Clinical global impressions in Alzheimer's clinical trials.

Authors:  L S Schneider; J T Olin
Journal:  Int Psychogeriatr       Date:  1996       Impact factor: 3.878

6.  Commentary on "Health economics and the value of therapy in Alzheimer's disease." Report from the Alzheimer's Association Research Roundtable on patient-reported outcomes and dementia research.

Authors:  Lori B Frank
Journal:  Alzheimers Dement       Date:  2007-07       Impact factor: 21.566

Review 7.  The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers.

Authors:  Napatkamon Ayutyanont; Jessica B S Langbaum; Suzanne B Hendrix; Kewei Chen; Adam S Fleisher; Michel Friesenhahn; Michael Ward; Camilo Aguirre; Natalia Acosta-Baena; Lucìa Madrigal; Claudia Muñoz; Victoria Tirado; Sonia Moreno; Pierre N Tariot; Francisco Lopera; Eric M Reiman
Journal:  J Clin Psychiatry       Date:  2014-06       Impact factor: 4.384

8.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.

Authors:  Clifford R Jack; David S Knopman; William J Jagust; Leslie M Shaw; Paul S Aisen; Michael W Weiner; Ronald C Petersen; John Q Trojanowski
Journal:  Lancet Neurol       Date:  2010-01       Impact factor: 44.182

9.  Compensatory mechanisms in higher-educated subjects with Alzheimer's disease: a study of 20 years of cognitive decline.

Authors:  Hélène Amieva; Hind Mokri; Mélanie Le Goff; Céline Meillon; Hélène Jacqmin-Gadda; Alexandra Foubert-Samier; Jean-Marc Orgogozo; Yaakov Stern; Jean-François Dartigues
Journal:  Brain       Date:  2014-02-27       Impact factor: 13.501

10.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.

Authors:  Victor L Villemagne; Samantha Burnham; Pierrick Bourgeat; Belinda Brown; Kathryn A Ellis; Olivier Salvado; Cassandra Szoeke; S Lance Macaulay; Ralph Martins; Paul Maruff; David Ames; Christopher C Rowe; Colin L Masters
Journal:  Lancet Neurol       Date:  2013-03-08       Impact factor: 44.182
View more
  5 in total

1.  Incident cognitive impairment: longitudinal changes in molecular, structural and cognitive biomarkers.

Authors:  Catherine M Roe; Beau M Ances; Denise Head; Ganesh M Babulal; Sarah H Stout; Elizabeth A Grant; Jason Hassenstab; Chengjie Xiong; David M Holtzman; Tammie L S Benzinger; Suzanne E Schindler; Anne M Fagan; John C Morris
Journal:  Brain       Date:  2018-11-01       Impact factor: 13.501

2.  Editorial: Preventive Trials for Alzheimer's Diseases: The Multi-domain and the Targeted Therapies Approaches Will Have to Be Associated.

Authors:  J Lin; B Dong; B Vellas
Journal:  J Nutr Health Aging       Date:  2016       Impact factor: 4.075

Review 3.  The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog): Modifications and Responsiveness in Pre-Dementia Populations. A Narrative Review.

Authors:  Jacqueline K Kueper; Mark Speechley; Manuel Montero-Odasso
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

Review 4.  Developing Effective Alzheimer's Disease Therapies: Clinical Experience and Future Directions.

Authors:  David R Elmaleh; Martin R Farlow; Peter S Conti; Ronald G Tompkins; Ljiljana Kundakovic; Rudolph E Tanzi
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

5.  Sex Mediates Relationships Between Regional Tau Pathology and Cognitive Decline.

Authors:  Rachel F Buckley; Matthew R Scott; Heidi I L Jacobs; Aaron P Schultz; Michael J Properzi; Rebecca E Amariglio; Timothy J Hohman; Danielle V Mayblyum; Zoe B Rubinstein; Lyssa Manning; Bernard J Hanseeuw; Elizabeth C Mormino; Dorene M Rentz; Keith A Johnson; Reisa A Sperling
Journal:  Ann Neurol       Date:  2020-08-31       Impact factor: 10.422
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.